Sesen Bio (NASDAQ: SESN)
Sesen Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sesen Bio Company Info
Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.
News & Analysis
Why Sesen Bio Stock Got Slammed Today
The company's hopeful words about its pipeline drug fell on deaf ears.
Why Sesen Bio Stock Crashed Today
Several law firms are taking sharp aim at the company.
Why Sesen Bio Stock Bounced Back Sharply Today
Some investors clearly believe all is not lost with the company's leading pipeline drug.
Why Sesen Bio Stock Fell off a Cliff Monday
The FDA dashes the company's hopes for its core pipeline drug...at least for now.
Why Sesen Bio Stock Is Soaring Today
The FDA accepted the company's filing for approval of Vicineum in treating bladder cancer.
Why Sesen Bio Stock Is Soaring Today
An analyst is very bullish about the biotech stock.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.